Full Press Release Details
| FOR IMMEDIATE RELEASE | Contact: | Jim Mackaness | ||
| Chief Financial Officer | ||||
| 650 940-4700 |
Mountain View, California
IRIDEX Reports Third Quarter 2008 Financial Results
IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the third quarter ended September 27, 2008.
Revenue for the third quarter of 2008 was $12.0 million, an 11.7% decrease from the $13.6 million reported for the third quarter of 2007. The Company
recorded net loss of $0.2 million or $(0.03) per diluted share for the third quarter of 2008, an improvement over the net loss of $1.2 million or $(0.15) per diluted share reported in the third quarter of 2007.
Ophthalmology revenues were $8.2 million in the third quarter of 2008, a 4.0% increase from $7.9 million in the comparable period of 2007. Comparing
third quarter 2008 vs. 2007, domestic ophthalmology revenues increased 17.0% to $5.3 million, international ophthalmology revenues decreased 13.2% to $2.9 million and ophthalmology recurring revenues, consisting of disposable products and service,
increased to 49.3% of our total ophthalmology revenues compared to 46.9% for the comparable period of 2007.
Total aesthetics revenues were
$3.8 million in the third quarter of 2008, a decrease of 33.4% from $5.7 million in the comparable period of 2007. In the third quarter of 2008, domestic aesthetics revenues decreased $0.6 million to $2.1 million and international aesthetics
revenues decreased $1.3 million to $1.7 million when compared to the same period in 2007.
Gross profit for the third quarter of 2008 was
$5.0 million, compared with $6.2 million for the third quarter of 2007. Gross margins were 41.6% and 45.6%, respectively. Operating expenses for the third quarter 2008 were $5.2 million compared with $7.2 million for 2007.
Mr. Theodore A. Boutacoff, President and CEO stated, Operationally we continue to make progress towards financial stability as
demonstrated by the substantial improvement in our quarterly operating performance year over year, reducing loss from operations from $1.1 million in the third quarter of 2007 to a loss of $0.2 million in the third quarter of 2008, primarily due to
reductions in operating expenses. Furthermore, we can report that we have met all of our obligations to AMS which has been a major cash burden for us during the first 9 months of 2008. In total, including principle, interest and payments for the
non-cancelable purchase orders we paid AMS $6.3 million in 2008, with $2.0 million of that being during the third quarter.
cash equivalents were $3.0 million as of September 27, 2008 down from $4.1 million as of June 28, 2008. However, working capital increased to $9.4 million from $8.9 million over the same period. Cash used in operations for the third
quarter was $1.0 million, which includes repaying the remaining amounts owed to AMS, and our bank debt as of September 27, 2008 was $6.0 million, which was unchanged from the balance as of June 28, 2008.
IRIDEX management will conduct a conference call later today, Tuesday, November 4, 2008 at 5:00 p.m. Eastern Time. Interested parties may access the live conference call via telephone by dialing (866) 250-4375 (US) or
(303) 262-2161 (International), or by visiting the Company s website at www.iridex.com. A telephone replay will be available beginning on Tuesday, November 4, 2008 through Tuesday, November 11, 2008 by dialing
(800) 405-2236 (US) or (303) 590-3000 (International) and entering Passcode 11122023#. In addition, later today an archived version of the webcast will be available on the Company s website at www.iridex.com.
IRIDEX Corporation is a leading
worldwide provider of therapeutic based laser systems, disposable laser probes and delivery devices to treat eye diseases in ophthalmology and skin disorders in the aesthetics market. IRIDEX products are sold in the United States through a direct
sales force and internationally through a combination of a direct sales force and a network of approximately 100 independent distributors into 107 countries. For further information, visit the Company s website at http://www.iridex.com.
Safe Harbor Statement
announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Act of 1934, as amended, relating to the Company s financial stability.
Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 29, 2007 and our Quarterly Report on Form 10-Q for the third quarter ended September 27, 2008 filed
with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.
Condensed Consolidated Statements of Operations
(In thousands, except per share
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 27, 2008 | September 29, 2007 | September 27, 2008 | September 29, 2007 | |||||||||||||
| Revenues | $ | 11,987 | $ | 13,575 | $ | 36,383 | $ | 41,390 | ||||||||
| Cost of revenues | 6,997 | 7,390 | 21,257 | 23,412 | ||||||||||||
| Gross profit | 4,990 | 6,185 | 15,126 | 17,978 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 972 | 1,319 | 2,995 | 4,636 | ||||||||||||
| Selling, general and administrative | 4,248 | 5,920 | 13,356 | 21,740 | ||||||||||||
| Total operating expenses | 5,220 | 7,239 | 16,351 | 26,376 | ||||||||||||
| Loss from operations | (230 | ) | (1,054 | ) | (1,225 | ) | (8,398 | ) | ||||||||
| Legal settlement | 800 | 2,500 | ||||||||||||||
| Interest and other expense, net | (54 | ) | (184 | ) | (426 | ) | (603 | ) | ||||||||
| Loss before income taxes | (284 | ) | (1,238 | ) | (851 | ) | (6,501 | ) | ||||||||
| Benefit (provision) for income taxes | 35 | (16 | ) | |||||||||||||
| Net loss | $ | (249 | ) | $ | (1,238 | ) | $ | (867 | ) | $ | (6,501 | ) | ||||
| Net loss per share - basic and diluted | $ | (0.03 | ) | $ | (0.15 | ) | $ | (0.10 | ) | $ | (0.80 | ) | ||||
| Shares used in computing net loss per share - basic and diluted | 8,824 | 8,218 | 8,824 | 8,165 |
Condensed Consolidated Balance Sheets
| September 27, 2008 | December 29, 2007 | |||||||
| (unaudited) | ||||||||
| Assets | ||||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | $ | 2,974 | $ | 5,809 | ||||
| Restricted cash | 3,800 | |||||||
| Accounts receivable, net | 9,215 | 8,876 | ||||||
| Inventories, net | 13,527 | 15,967 | ||||||
| Prepaids and other current assets | 1,264 | 1,051 | ||||||
| Total current assets | 26,980 | 35,503 | ||||||
| Property and equipment, net | 1,128 | 1,621 | ||||||
| Goodwill | 3,239 | 3,239 | ||||||
| Other intangible assets, net | 4,185 | 5,944 | ||||||
| Other long term assets | 224 | 347 | ||||||
| Total assets | 35,756 | 46,654 | ||||||
| Liabilities and Stockholders Equity | ||||||||
| Current Liabilities: | ||||||||
| Accounts payable | $ | 2,593 | $ | 2,887 | ||||
| Bank line of credit | 6,000 | 4,863 | ||||||
| Accrued compensation | 1,680 | 2,024 | ||||||
| Accrued expenses | 3,235 | 7,809 | ||||||
| Accrued warranty | 1,258 | 1,895 | ||||||
| Deferred revenue | 2,805 | 3,350 | ||||||
| Bank term loan-current portion | 5,016 | |||||||
| Total current liabilities | 17,571 | 27,844 | ||||||
| Stockholders Equity: | ||||||||
| Convertible preferred stock, $.01 par value: | ||||||||
| Authorized: 2,000,000 shares; Issued and outstanding: 500,000 shares in 2008 and 2007 | 5 | 5 | ||||||
| Common Stock, $.01 par value: | ||||||||
| Authorized: 30,000,000 shares; Issued and outstanding: 8,824,301 shares in 2008 and 2007 | 89 | 89 | ||||||
| Additional paid-in capital | 39,087 | 38,695 | ||||||
| Accumulated other comprehensive loss | (238 | ) | (88 | ) | ||||
| Treasury stock, at cost | (430 | ) | (430 | ) | ||||
| Accumulated deficit | (20,328 | ) | (19,461 | ) | ||||
| Total stockholders equity | 18,185 | 18,810 | ||||||
| Total liabilities and stockholders equity | $ | 35,756 | $ | 46,654 |